Literature DB >> 17916540

The narcotic bowel syndrome: clinical features, pathophysiology, and management.

David M S Grunkemeier1, Joseph E Cassara, Christine B Dalton, Douglas A Drossman.   

Abstract

Narcotic bowel syndrome (NBS) is a subset of opioid bowel dysfunction that is characterized by chronic or frequently recurring abdominal pain that worsens with continued or escalating dosages of narcotics. This syndrome is underrecognized and may be becoming more prevalent. In the United States this may be the result of increases in using narcotics for chronic nonmalignant painful disorders, and the development of maladaptive therapeutic interactions around its use. NBS can occur in patients with no prior gastrointestinal disorder who receive high dosages of narcotics after surgery or acute painful problems, and among patients with functional gastrointestinal disorders or other chronic gastrointestinal diseases who are managed by physicians who are unaware of the hyperalgesic effects of chronic opioids. The evidence for the enhanced pain perception is based on the following: (1) activation of excitatory antianalgesic pathways within a bimodal opioid regulation system, (2) descending facilitation of pain at the rostral ventral medulla and pain facilitation via dynorphin and cholecystokinin activation, and (3) glial cell activation that produces morphine tolerance and enhances opioid-induced pain. Treatment involves early recognition of the syndrome, an effective physician-patient relationship, graded withdrawal of the narcotic according to a specified withdrawal program, and the institution of medications to reduce withdrawal effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916540      PMCID: PMC2074872          DOI: 10.1016/j.cgh.2007.06.013

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  72 in total

1.  Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and monkey: possible site of opiate-CCK analgesic interactions.

Authors:  J R Ghilardi; C J Allen; S R Vigna; D C McVey; P W Mantyh
Journal:  J Neurosci       Date:  1992-12       Impact factor: 6.167

Review 2.  Opioid guidelines in the management of chronic non-cancer pain.

Authors:  Andrea M Trescot; Mark V Boswell; Sairam L Atluri; Hans C Hansen; Timothy R Deer; Salahadin Abdi; Joseph F Jasper; Vijay Singh; Arthur E Jordan; Benjamin W Johnson; Roger S Cicala; Elmer E Dunbar; Standiford Helm; Kenneth G Varley; P K Suchdev; John R Swicegood; Aaron K Calodney; Bentley A Ogoke; W Stephen Minore; Laxmaiah Manchikanti
Journal:  Pain Physician       Date:  2006-01       Impact factor: 4.965

Review 3.  Incidence, prevalence, and management of opioid bowel dysfunction.

Authors:  M Pappagallo
Journal:  Am J Surg       Date:  2001-11       Impact factor: 2.565

Review 4.  Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons.

Authors:  S M Crain; K F Shen
Journal:  Trends Pharmacol Sci       Date:  1990-02       Impact factor: 14.819

5.  The involvement of glial cells in the development of morphine tolerance.

Authors:  P Song; Z Q Zhao
Journal:  Neurosci Res       Date:  2001-03       Impact factor: 3.304

6.  An application of behavior modification technique to a problem of chronic pain.

Authors:  W E Fordyce; R S Fowler; B DeLateur
Journal:  Behav Res Ther       Date:  1968-02

7.  Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.

Authors:  Daniel M Paulson; Daniel T Kennedy; Roger A Donovick; Randall L Carpenter; Maryann Cherubini; Lee Techner; Wei Du; Yuju Ma; William K Schmidt; Bruce Wallin; David Jackson
Journal:  J Pain       Date:  2005-03       Impact factor: 5.820

Review 8.  Oral methadone for chronic noncancer pain: a systematic literature review of reasons for administration, prescription patterns, effectiveness, and side effects.

Authors:  Juan Alberto Sandoval; Andrea D Furlan; Angela Mailis-Gagnon
Journal:  Clin J Pain       Date:  2005 Nov-Dec       Impact factor: 3.442

Review 9.  Peripheral opioids for functional GI disease: a reappraisal.

Authors:  Anthony Lembo
Journal:  Dig Dis       Date:  2006       Impact factor: 2.404

10.  The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome.

Authors:  S K Joishy; D Walsh
Journal:  J Pain Symptom Manage       Date:  1998-11       Impact factor: 3.612

View more
  74 in total

1.  Avoiding analgesic escalation and excessive healthcare utilization in severe irritable bowel syndrome: a role for intramuscular anticholinergics?

Authors:  James S Pearson; Christine Pollard; Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2014-11       Impact factor: 4.409

Review 2.  When is irritable bowel syndrome not irritable bowel syndrome? Diagnosis and treatment of chronic functional abdominal pain.

Authors:  Madhusudan Grover
Journal:  Curr Gastroenterol Rep       Date:  2012-08

Review 3.  Evolving paradigms in the treatment of opioid-induced bowel dysfunction.

Authors:  Jakob Lykke Poulsen; Christina Brock; Anne Estrup Olesen; Matias Nilsson; Asbjørn Mohr Drewes
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

4.  Small intestine strictures in opium addicts: An unrecognized cause of intestinal obstruction.

Authors:  Ashish Joshi; Sushil Falodia; Naveen Kumar; R L Solanki
Journal:  Indian J Gastroenterol       Date:  2018-03-07

Review 5.  Strategies to Identify and Reduce Opioid Misuse Among Patients with Gastrointestinal Disorders: A Systematic Scoping Review.

Authors:  Salva N Balbale; Itishree Trivedi; Linda C O'Dwyer; Megan C McHugh; Charlesnika T Evans; Neil Jordan; Laurie A Keefer
Journal:  Dig Dis Sci       Date:  2017-08-05       Impact factor: 3.199

6.  Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids.

Authors:  Mohamed Noureldin; Peter D R Higgins; Shail M Govani; Shirley Cohen-Mekelburg; Brooke C Kenney; Ryan W Stidham; Jennifer F Waljee; Akbar K Waljee
Journal:  Aliment Pharmacol Ther       Date:  2018-11-14       Impact factor: 8.171

7.  Narcotic use for inflammatory bowel disease and risk factors during hospitalization.

Authors:  Millie D Long; Edward L Barnes; Hans H Herfarth; Douglas A Drossman
Journal:  Inflamm Bowel Dis       Date:  2011-07-07       Impact factor: 5.325

8.  The impact of opiate pain medications and psychoactive drugs on the quality of colon preparation in outpatient colonoscopy.

Authors:  Vladimir M Kushnir; Pavan Bhat; Reena V Chokshi; Alexander Lee; Brian B Borg; Chandra Prakash Gyawali; Gregory S Sayuk
Journal:  Dig Liver Dis       Date:  2013-09-06       Impact factor: 4.088

Review 9.  Common Functional Gastroenterological Disorders Associated With Abdominal Pain.

Authors:  Adil E Bharucha; Subhankar Chakraborty; Christopher D Sletten
Journal:  Mayo Clin Proc       Date:  2016-08       Impact factor: 7.616

10.  Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest.

Authors:  Melena D Bellin; Martin L Freeman; Andres Gelrud; Adam Slivka; Alfred Clavel; Abhinav Humar; Sarah J Schwarzenberg; Mark E Lowe; Michael R Rickels; David C Whitcomb; Jeffrey B Matthews; Stephen Amann; Dana K Andersen; Michelle A Anderson; John Baillie; Geoffrey Block; Randall Brand; Suresh Chari; Marie Cook; Gregory A Cote; Ty Dunn; Luca Frulloni; Julia B Greer; Michael A Hollingsworth; Kyung Mo Kim; Alexander Larson; Markus M Lerch; Tom Lin; Thiruvengadam Muniraj; R Paul Robertson; Seth Sclair; Shalinender Singh; Rachelle Stopczynski; Frederico G S Toledo; Charles Melbern Wilcox; John Windsor; Dhiraj Yadav
Journal:  Pancreatology       Date:  2013-11-13       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.